Trial Profile
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Mar 2011 New trial record